Lexeo Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

New York NY US

Primary Industry

Biotechnology

About

Based in New York, US, and founded in 2018 by Ronald G. Crystal, Lexeo Therapeutics, Inc. is a biotechnology company that develops adeno-associated virus (AAV)-mediated therapies. In March 2024, Lexeo Therapeutics, Inc. raised USD 95 million in PIPE funding co-led by Braidwell, Adage Capital Management, RA Capital Management, Surveyor Capital, and Novo Holdings. The company trades on NASDAQ under the ticker symbol LXEO. Lexeo Therapeutics develops and provides AAV (adeno-associated virus)-mediated therapies to treat patients with genetic diseases. The company's pipeline includes three clinical-stage gene therapy programs in monogenic diseases and up to 15 potential additional AAV gene therapy programs in monogenic and acquired diseases. The company’s preclinical pipeline includes monogenic diseases as well as hereditary and acquired diseases. The company plans to use the funds raised in March 2024 to enhance its ongoing clinical-stage programs and for working capital and general corporate purposes.

Current Investors

Alexandria Venture Investments, Invus, Longitude Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals

Website

www.lexeotx.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Deals

Deals Type
PIPE

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	Lexeo Therapeutics, Inc.	11 Mar 2024

Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.